Persistent Posttreatment Fatigue in Thyroid Cancer Survivors : A Scoping Review - 01/06/14
, Asima Naeem, BSc a, Jennifer Jones, PhD c, d, Julia Lowe, MBChB, MMedSci b, e, Philip Segal, MD, FRCPC a, b, f, Jeannette Goguen, MD, MEd, FRCPC b, g, Jeremy Gilbert, MD, FRCPC b, e, Afshan Zahedi, MD, FRCPC b, f, h, Catherine Kelly, MD, FRCPC b, h, Shereen Ezzat, MD, FRCPC iRésumé |
The relevance of persistent posttreatment fatigue (PPF) to thyroid cancer (TC) survivor populations is not known. This article presents a scoping review, which is an overview of published research activity. Uncontrolled data suggest that PPF is one of the most common complaints in TC survivors. Furthermore, statistically significantly worse levels of fatigue were reported in TC survivors, compared with the general population or healthy controls. There was some inconsistency among PPF risk factors. More research is needed on PPF in TC survivors, including long-term prospective cohort studies, research on fatigue severity prevalence, and randomized controlled trials of treatment strategies.
Le texte complet de cet article est disponible en PDF.Keywords : Thyroid cancer, Fatigue, Vitality, Quality of life, Survivorship
Plan
| Funding: This work was funded in part by a University of Toronto Department of Medicine Strategic Innovation Fund grant. A.M. Sawka currently holds a Chair in Health Services Research from Cancer Care Ontario, funded by the Ontario Ministry of Health and Long-term Care. |
|
| Disclosures: Other than the academic funding listed earlier, the authors have no relevant disclosures to declare. |
Vol 43 - N° 2
P. 475-494 - juin 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
